Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2/3 2Phase NA 1Phase 3 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 16Neoplasms 2Urogenital Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Bulbo-Spinal Atrophy, X-Linked 1Adenocarcinoma 1

Interventions

Leucovorin 22Fluorouracil 22Paclitaxel 21Gemcitabine 21Docetaxel 21Capecitabine 21Irinotecan 16Carboplatin 15Radiosurgery 14Oxaliplatin 13Cisplatin 13Bevacizumab 13Zoledronic Acid 12pembrolizumab 11Radiotherapy 11Fulvestrant 11palbociclib 9Pemetrexed 9Drug Therapy 9130-nm albumin-bound paclitaxel 9Surgical Procedures, Operative 7Letrozole 7Ibandronic Acid 7abemaciclib 6Trastuzumab 6Prednisone 6Vinorelbine 5Folfox protocol 5Floxuridine 5Doxorubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasm Metastasis × abiraterone × Clear all
NCT05288166 2025-06-27

CYCLONE 3

Eli Lilly and Company

Phase 3 Active not recruiting
925 enrolled 12 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡